Metabolic Disease

  • Agentix is a clinical-stage biotechnology company developing therapeutic agents for the treatment of the following metabolic diseases:
    • Type 2 diabetes mellitus
    • Obesity
    • Non-alcoholic fatty liver disease (NAFLD)
    • Non-alcoholic steatohepatitis (NASH)
  • We currently have a portfolio of novel peripherally-acting small molecule

Therapeutic Strategy

Modulation of the Endocannabinoid System (ECS)

• The ECS is key to the regulatory system
governing metabolism.

• Blockade of peripheral CB1 receptors results in:

      · Sustained weight loss
      · Control of glucose and lipid metabolism
      · Improved insulin control
      · Modulation of gastrointestinal function

Role of the Endocannabinoid System in Management of Patients with Type 2 Diabetes Mellitus and Cardiovascular Risk Factors; Stephen N. Davis, MD, FRCP & Jennifer M. Perkins, MD; AACE Endocrine Practice Volume 13, ISSUE 7, P790-804, November 01, 2007

Wikimedia Commons; Schematic sketch showing the transport types at the blood-brain barrier by Armin Kübelbeck; November 13, 2011

Restrict Therapeutic Activity to the Periphery

By increasing the topological polar surface area (tPSA), our molecules do not


 The results of this strategy is demonstrated in our pre-clinical models:

  • No significant accumulation in the brain
  • Accumulation observed in the thigh muscle, heart,
    kidney and liver
  • Most significant accumation, by regional
    distribution, was observed in the liver

Hung, Ming-Shiu, et al, Bioorganic & Medicinal Chemistry 27 (2019) 216–223

AGTX-2004[F18] PET scan coronal cross section image at 90 min post injection

  • Deep blue (liver), cyan blue (heart), green (thigh
    muscle), pink (kidney), yellow (brain)
  • Injection dose 170 μCi/0.15 mL (1.57×10−10 mol)